Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00615940 |
|
Recruitment Status :
Completed
First Posted : February 14, 2008
Last Update Posted : February 28, 2014
|
Sponsor:
Heidelberg Pharma AG
Collaborator:
U.S. Army Medical Research and Development Command
Information provided by (Responsible Party):
Heidelberg Pharma AG
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | December 2011 |
| Actual Study Completion Date : | April 2012 |
| Certification/Extension First Submitted : | January 28, 2014 |